SE0203747D0 - New use - Google Patents

New use

Info

Publication number
SE0203747D0
SE0203747D0 SE0203747A SE0203747A SE0203747D0 SE 0203747 D0 SE0203747 D0 SE 0203747D0 SE 0203747 A SE0203747 A SE 0203747A SE 0203747 A SE0203747 A SE 0203747A SE 0203747 D0 SE0203747 D0 SE 0203747D0
Authority
SE
Sweden
Prior art keywords
new use
deoxypodophyllotoxin
picropodophyllin
glioblastoma
neuroblastoma
Prior art date
Application number
SE0203747A
Other languages
Swedish (sv)
Inventor
Magnus Axelsson
Olle Larsson
Original Assignee
Karolinska Innovations Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab
Priority to SE0203747A priority Critical patent/SE0203747D0/en
Publication of SE0203747D0 publication Critical patent/SE0203747D0/en
Priority to PCT/SE2003/002012 priority patent/WO2004055022A1/en
Priority to AU2003288858A priority patent/AU2003288858A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention refers to the use of certain cyclolignans as specific inhibitors of the insulin-like growth factor-1 receptor for treatment of the malignant diseases neuroblastoma, myeloma, glioblastoma and lung cancer, as well as benign tumours. Preferred compounds are picropodophyllin and deoxypodophyllotoxin.
SE0203747A 2002-12-18 2002-12-18 New use SE0203747D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE0203747A SE0203747D0 (en) 2002-12-18 2002-12-18 New use
PCT/SE2003/002012 WO2004055022A1 (en) 2002-12-18 2003-12-18 Use of cyclolignans as inhibitors of igf-1 receptor for treatment of malignat diseases
AU2003288858A AU2003288858A1 (en) 2002-12-18 2003-12-18 Use of cyclolignans as inhibitors of igf-1 receptor for treatment of malignat diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0203747A SE0203747D0 (en) 2002-12-18 2002-12-18 New use

Publications (1)

Publication Number Publication Date
SE0203747D0 true SE0203747D0 (en) 2002-12-18

Family

ID=20289900

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0203747A SE0203747D0 (en) 2002-12-18 2002-12-18 New use

Country Status (3)

Country Link
AU (1) AU2003288858A1 (en)
SE (1) SE0203747D0 (en)
WO (1) WO2004055022A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080171318A1 (en) * 2004-09-30 2008-07-17 Epigenomics Ag Epigenetic Methods and Nucleic Acids for the Detection of Lung Cell Proliferative Disorders
WO2009100349A1 (en) 2008-02-09 2009-08-13 The Trustees Of Columbia University In The City Of New York Analogues of (-)-picropodophyllin, synthesis and uses thereof
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
MX2013003859A (en) * 2010-10-08 2013-07-29 Axelar Ab Picropodophyllin polymorphs b or c for use in cancer therapy.
CA2812926A1 (en) * 2010-10-08 2012-04-12 Axelar Ab Picropodophyllin monohydrate or polymorph a in cancer therapy
WO2013132263A1 (en) * 2012-03-09 2013-09-12 Axelar Ab Picropodophyllin derivatives for use in therapy
KR102090554B1 (en) * 2018-04-13 2020-03-18 한국원자력의학원 Radiosensitizer containing β-Apopicropodophyllin as an active ingredient

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102168D0 (en) * 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds

Also Published As

Publication number Publication date
AU2003288858A1 (en) 2004-07-09
WO2004055022A1 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
NO2017019I1 (en) Diarylhydantoin compound, pharmaceutical composition and use thereof
BRPI0510177B8 (en) compound, pharmaceutical composition and use thereof
DE60318177D1 (en) RHO-KINASE INHIBITORS
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
EA201071100A1 (en) Pyridyl-containing SIGNAL TRANSMISSION TRANSMITTER INHIBITORS THROUGH HEDGEHOG
PA8571001A1 (en) 2- (2,6-DICLOROPHENYL) -DIARYLIMIDAZOLS
EA200501504A1 (en) Cannabinoid receptor ligands and their use
EA200701930A1 (en) Derivatives of pyrimidine for the treatment of hyperproliferative disorders
EA200870415A1 (en) QUINAZOLINS TO INHIBIT PDK 1
UA116188C2 (en) PHOSPHATIDYLINOSITE-3-KINASE INHIBITORS AND METHODS OF USE
EA200802213A1 (en) METHODS OF TREATING BLOOD DISEASES
EA200501430A1 (en) Cannabinoid receptor ligands and their use
EA201890903A1 (en) CONNECTIONS OF PERIDEL INHIBITORS OF TRANSMISSION OF SIGNALS BY HEDGEHOG PROTEIN, METHOD OF THEIR RECEIVING, COMPOSITION AND METHODS OF TREATING CANCER AND INHIBITING ANGIOGENESIS AND HEDGEHOG IN CELLS
MX2007002269A (en) Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain.
MX2007011545A (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors.
NO20091661L (en) Use of pegylated IL-10 to treat cancer
EA200702363A1 (en) NEW HISTAMINE H-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS
ATE458487T1 (en) TUMOR TREATMENT WITH GLIOTOXIN DERIVATIVES
EA201170617A1 (en) PYRAZOLYLAMINOPIRIDINE AS FAK INHIBITORS
TW200740812A (en) 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
EA201170344A1 (en) AZAINDOL IAP INHIBITORS
ATE542796T1 (en) N-SULFONYLCARBOXIMIDAMIDE COMPOUNDS AS APOPTOSIS PROMOTERS
ATE549024T1 (en) QUINAZOLINE POTASSIUM CHANNEL INHIBITORS
SE0203747D0 (en) New use
ATE359283T1 (en) SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION